Calcimedica, INC. (CALC) — SEC Filings

Overview

Calcimedica, INC. (CALC) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 12, 2025: CalciMedica, Inc. (CALC) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $18.802 million, a 99.1% increase from the $9.442 million loss in the same period of 2024. This was primarily driven by a substantial increase in research and development expen

Sentiment Summary

Across 45 filings, the sentiment breakdown is: 4 bullish, 3 bearish, 37 neutral, 1 mixed. The dominant filing sentiment for Calcimedica, INC. is neutral.

Filing Type Overview

Calcimedica, INC. (CALC) has filed 1 4, 5 10-Q, 17 8-K, 2 DEFA14A, 2 DEF 14A, 2 10-K, 1 SC 13D, 5 SC 13G/A, 3 SC 13D/A, 5 SC 13G, 1 10-K/A, 1 8-K/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (45)

• 4 Filing — 4 · Apr 8, 2026
• CalciMedica's Net Loss Doubles Amid Rising R&D, Cash Dwindles — 10-Q · Nov 12, 2025 Risk: high
  CalciMedica, Inc. (CALC) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $18.802 million, a 99.1% increase fr
• 8-K Filing — 8-K · Nov 6, 2025
• CalciMedica Posts $21.3M Net Loss, Secures $15M Loan for R&D — 10-Q · Aug 12, 2025 Risk: high
  CalciMedica, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The company posted a net loss
• CalciMedica Files 8-K: Director Changes, Officer Appointments — 8-K · Jun 27, 2025 Risk: medium
  On June 24, 2025, CalciMedica, Inc. filed an 8-K report detailing the election of new directors, the appointment of certain officers, and compensatory arrangeme
• CalciMedica Files Proxy Materials — DEFA14A · Jun 9, 2025 Risk: low
  CalciMedica, Inc. filed a Definitive Additional Materials proxy statement on June 9, 2025. This filing relates to the company's proxy materials, which are typic
• CalciMedica Appoints PricewaterhouseCoopers as New Auditor — 8-K · Jun 6, 2025 Risk: low
  On June 3, 2025, CalciMedica, Inc. filed an 8-K report indicating a change in its certifying accountant. The company has appointed PricewaterhouseCoopers LLP as
• CalciMedica Files 10-Q, Details Financials — 10-Q · May 14, 2025 Risk: medium
  CalciMedica, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information, including fair value measurements for recurring
• CalciMedica Files Proxy Materials — DEFA14A · Apr 30, 2025 Risk: low
  CalciMedica, Inc. filed a Definitive Additional Materials proxy statement on April 30, 2025. This filing relates to the company's proxy materials and does not i
• DEF 14A Filing — DEF 14A · Apr 29, 2025
• 10-K Filing — 10-K · Mar 27, 2025
• CalciMedica Reports Material Agreement and Equity Sales — 8-K · Mar 5, 2025 Risk: medium
  On February 28, 2025, CalciMedica, Inc. entered into a Material Definitive Agreement related to a direct financial obligation. The company also reported on the
• CalciMedica, Inc. Files 8-K Report — 8-K · Mar 4, 2025 Risk: low
  On March 4, 2025, CalciMedica, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, and other events. No specific financia
• CalciMedica Appoints Dr. Jonathan Lim to Board — 8-K · Jan 14, 2025 Risk: low
  On January 10, 2025, CalciMedica, Inc. announced the election of Dr. Jonathan Lim to its Board of Directors. Dr. Lim, a seasoned executive with experience in th
• CalciMedica, Inc. Files 8-K Report — 8-K · Dec 20, 2024 Risk: low
  On December 20, 2024, CalciMedica, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific mate
• Sanderling Ventures Discloses Stake in CalciMedica — SC 13D · Nov 26, 2024 Risk: medium
  On November 26, 2024, Sanderling Venture Partners VI LP and its affiliates filed an SC 13D, reporting beneficial ownership of CalciMedica, Inc. The filing indic
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• CalciMedica Files 8-K on Financials — 8-K · Nov 13, 2024 Risk: low
  On November 13, 2024, CalciMedica, Inc. filed an 8-K report detailing its results of operations and financial condition. The filing includes financial statement
• SC 13G/A Filing — SC 13G/A · Nov 13, 2024
• CalciMedica Appoints New CMO, Adds Directors — 8-K · Nov 8, 2024 Risk: medium
  On November 6, 2024, CalciMedica, Inc. announced the appointment of Dr. Jonathan Lim as Chief Medical Officer and the election of Dr. Lim and Ms. Sarah P. Kelly
• Valence Investments Amends CalciMedica Stake — SC 13D/A · Nov 6, 2024 Risk: medium
  On November 6, 2024, Valence Investments SPV VI, LLC, along with A. Rachel Leheny and Eric W. Roberts, filed an amendment (No. 3) to their Schedule 13D for Calc
• CalciMedica, Inc. Files 8-K with Material Definitive Agreement — 8-K · Oct 31, 2024 Risk: medium
  On October 30, 2024, CalciMedica, Inc. entered into a Material Definitive Agreement. The company also reported other events and filed financial statements and e
• CalciMedica, Inc. Files 8-K with Corporate Updates — 8-K · Oct 30, 2024 Risk: low
  CalciMedica, Inc. filed an 8-K on October 30, 2024, reporting on various events. The filing includes information about the company's incorporation in Delaware,
• CalciMedica Appoints New CMO, Elects Director — 8-K · Aug 27, 2024 Risk: medium
  CalciMedica, Inc. announced on August 27, 2024, the appointment of Dr. Robert J. Valeri as Chief Medical Officer and the election of Ms. Jennifer L. Jones to it
• CalciMedica, Inc. Files Q2 2024 10-Q — 10-Q · Aug 12, 2024 Risk: medium
  CalciMedica, Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly known as Graybug Vision, Inc., is focused on pharmaceutical preparat
• CalciMedica Files Proxy Statement for August Shareholder Meeting — DEF 14A · Jul 16, 2024 Risk: low
  CalciMedica, Inc. filed its definitive proxy statement on July 16, 2024, for its annual meeting of stockholders scheduled for August 27, 2024. The filing outlin
• SC 13G Filing — SC 13G · Jul 8, 2024
• CalciMedica Files 8-K: Reg FD, Other Events, Exhibits — 8-K · Jun 27, 2024 Risk: low
  On June 27, 2024, CalciMedica, Inc. filed an 8-K report detailing a Regulation FD Disclosure and Other Events. The filing also includes Financial Statements and
• CalciMedica, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 13, 2024 Risk: medium
  CalciMedica, Inc. (CALC) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. CalciMedica, Inc. filed a 10-Q report for the period ending March 31, 202
• CalciMedica, Inc. Files Amendment to Annual Report — 10-K/A · Apr 29, 2024 Risk: low
  CalciMedica, Inc. (CALC) filed a Amended Annual Report (10-K/A) with the SEC on April 29, 2024. CalciMedica, Inc. filed an amendment (10-K/A) to its annual repo
• CalciMedica Changes Auditors to BDO USA, P.A. — 8-K · Apr 10, 2024 Risk: low
  On April 5, 2024, CalciMedica, Inc. announced a change in its principal accounting firm, dismissing PricewaterhouseCoopers LLP and engaging BDO USA, P.A. as its
• CalciMedica, Inc. Files 8-K Report — 8-K · Mar 29, 2024 Risk: low
  On March 29, 2024, CalciMedica, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating routine corporate disclosu
• CalciMedica, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 28, 2024 Risk: medium
  CalciMedica, Inc. (CALC) filed a Annual Report (10-K) with the SEC on March 28, 2024. CalciMedica, Inc. filed its 2023 Annual Report on Form 10-K on March 28, 2
• CalciMedica Files 8-K Report on Feb 13, 2024 — 8-K · Feb 13, 2024 Risk: low
  CalciMedica, Inc. filed an 8-K Current Report with the SEC on February 13, 2024. The filing indicates disclosures under Regulation FD, Other Events, and Financi
• Soleus Capital Amends CalciMedica Stake on Feb 5 — SC 13G/A · Feb 8, 2024 Risk: medium
  Soleus Capital Master Fund, L.P. filed an Amendment No. 1 to Schedule 13G on February 8, 2024, indicating a change in their beneficial ownership of CalciMedica,
• Valence Investments Group Cuts CalciMedica Stake to 4.9% — SC 13D/A · Feb 8, 2024 Risk: medium
  Valence Investments SPV VI, LLC, along with Valence Investments SPV IV, LLC, Valence Investments SPV V, LLC, Eric Roberts, and Rachel Leheny, filed an amendment
• BML Investment Partners Amends CalciMedica Stake — SC 13G/A · Feb 7, 2024
  BML Investment Partners, L.P. filed an amended Schedule 13G/A on February 7, 2024, indicating their ownership of CalciMedica, Inc. common stock as of December 3
• OrbiMed Amends CalciMedica 13D Filing, Updates Ownership — SC 13D/A · Feb 5, 2024
  OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC filed an Amendment No. 4 to their Schedule 13D for CalciMedica, Inc. on February 5, 2024. This filing updates
• Aisling Capital V Discloses 5.1% Stake in CalciMedica — SC 13G · Feb 1, 2024
  Aisling Capital V, LP, a New York-based investment firm, along with its affiliates Aisling Capital Partners V LLC, Aisling Capital Partners V, LP, Dr. Andrew Sc
• Deerfield Mgmt Reports Significant Stake in CalciMedica (CALC) — SC 13G · Feb 1, 2024
  Deerfield Mgmt, L.P., a New York-based investment firm, reported on February 1, 2024, that it holds a significant stake in CalciMedica, Inc. (NASDAQ: CALC). Thi
• Stonepine Capital Takes 5.1% Stake in CalciMedica — SC 13G · Jan 31, 2024
  Stonepine Capital Management, LLC, a Delaware-incorporated investment firm, has disclosed a significant stake in CalciMedica, Inc. (NASDAQ: CALC), a pharmaceuti
• Soleus Capital Discloses 9.9% Passive Stake in CalciMedica (CALC) — SC 13G · Jan 26, 2024
  Soleus Capital Master Fund, L.P., a hedge fund, along with its affiliates Soleus Capital Group, LLC, Soleus Capital, LLC, and Guy Levy, reported a significant p
• CalciMedica Amends 8-K Filing on Equity Sales, Financials — 8-K/A · Jan 24, 2024
  CalciMedica, Inc. filed an 8-K/A Amendment No. 1 on January 24, 2024, updating its previous 8-K filing from January 19, 2024. This amendment primarily serves to
• CalciMedica Raises $5M in Private Placement of Stock & Warrants — 8-K · Jan 22, 2024
  CalciMedica, Inc. (NASDAQ: CALC) announced on January 19, 2024, that it entered into a material definitive agreement, specifically a Securities Purchase Agreeme

Risk Profile

Risk Assessment: Of CALC's 29 recent filings, 2 were flagged as high-risk, 13 as medium-risk, and 14 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Calcimedica, INC.'s most recent 10-Q filing (Nov 12, 2025):

• Revenue: $0
• Net Income: -$18.802M
• EPS: -$1.28
• Debt-to-Equity: N/A
• Cash Position: $5.470M
• Operating Margin: N/A
• Total Assets: $14.913M
• Total Debt: $11.500M

Key Executives

• Dr. Jonathan Lim
• FRED A. MIDDLETON
• TIMOTHY C. MILLS
• Ms. Sarah P. Kelly
• A. Rachel Leheny
• Eric W. Roberts
• Dr. Robert J. Valeri
• Ms. Jennifer L. Jones
• Guy Levy

Industry Context

CalciMedica operates in the biotechnology sector, a highly competitive and capital-intensive industry. Companies in this space focus on developing novel therapeutics, often requiring substantial investment in research and development with long timelines and high failure rates. Success is heavily dependent on clinical trial outcomes, regulatory approvals, and securing ongoing financing.

Top Tags

institutional-ownership (6) · 8-K (5) · amendment (5) · biotech (5) · filing (4) · corporate-governance (3) · pharmaceuticals (3) · 10-Q (3) · financials (3) · ownership-change (3)

Key Numbers

• Net Loss: $18.802M — for the nine months ended September 30, 2025, nearly double the prior year
• Cash and Cash Equivalents: $5.470M — as of September 30, 2025, down 31% from December 31, 2024
• Research and Development Expenses: $12.127M — for the nine months ended September 30, 2025, up from $10.647M in 2024
• Promissory Note: $8.900M — new long-term liability as of September 30, 2025
• Warrant Liability: $2.600M — as of September 30, 2025, up from $1.700M at December 31, 2024
• Common Stock Outstanding: 14,409,431 — as of November 6, 2025
• Net Loss Per Share: $1.28 — for the nine months ended September 30, 2025, up from $0.88 in 2024
• Net Cash Provided by Financing Activities: $11.458M — for the nine months ended September 30, 2025
• Revenue: $0 — No revenue reported for the three and six months ended June 30, 2025, indicating pre-commercial stage.
• R&D Expense: $12.5M — Research and development expenses for the six months ended June 30, 2025, reflecting ongoing clinical trial costs.
• G&A Expense: $8.8M — General and administrative expenses for the six months ended June 30, 2025.
• Term Loan Facility: $15.0M — New financing secured from Avenue Venture Opportunities Fund II, L.P. on February 28, 2025.
• Accumulated Deficit: $305.8M — Total accumulated deficit as of June 30, 2025, indicating historical losses.
• Period End Date: 20250331 — The financial reporting period covered by the 10-Q.
• Filing Date: 20250514 — The date the 10-Q was officially submitted to the SEC.

Forward-Looking Statements

• {"claim":"CalciMedica's stock price may experience short-term volatility due to the reduced institutional stake.","entity":"CalciMedica, Inc.","targetDate":"Q1 2024","confidence":"medium"}
• {"claim":"Other institutional investors might re-evaluate their positions in CalciMedica following this filing.","entity":"Institutional Investors","targetDate":"Q2 2024","confidence":"low"}

Frequently Asked Questions